08:00 , Nov 20, 2008 |  BC Innovations  |  Tools & Techniques

Table 1. Oncolytic virus therapies

Table 1. Oncolytic virus therapies...
07:00 , Jun 13, 2005 |  BC Week In Review  |  Clinical News

Introgen preclinical data

In a hamster model of cancer, INGN 007 significantly inhibited tumor growth and metastasis. INGN licensed the replicating adenovirus vector overexpressing ADP from VirRx Inc. (St. Louis, Mo.). Data were presented at the American Society...
07:00 , May 24, 2004 |  BC Week In Review  |  Clinical News

Introgen preclinical data

Researchers published in Cancer Research that INGN 007 (VRX-007) efficiently killed colon and lung cancer cells in culture and completely suppressed tumor growth in a mouse model of lung cancer. In a mouse model of...
07:00 , Jun 16, 2003 |  BC Week In Review  |  Clinical News

Introgen, VirRx Inc. preclinical data

In INGN 007 suppressed human cancer xenografts in nude mice. INGN exclusively licensed the technology from VirRx. Data were presented at the American Society of Gene Therapy meeting in Washington D.C. Introgen Therapeutics Inc. (INGN),...